Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675970 | 0.85 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL16530082 | 0.85 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL1675968 | 0.84 | KMT2A (0.57) | HSD11B1 | |
| SCHEMBL15100849 | 0.81 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL15090641 | 0.81 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL16666619 | 0.80 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL27783377 | 0.79 | HSD11B1 (0.64) | HSD11B1 | |
| SCHEMBL15090598 | 0.78 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL15100711 | 0.78 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL12586231 | 0.78 | HSD11B1 (0.53) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614080-B2 | Method for producing hydroxylated adamantane using cytochrome P450 | SHIONOGI & CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| US-20130072668-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | SHIONOGI & CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8383381-B2 | Method for producing hydroxylated adaivjantane using cytochrome P450 | Shjonogi & Co., Ltd. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110086405-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | SHIONOGI & CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2221380-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | Shionogi & Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072668-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | CYP3A5, CYP1A2, POR | HSD11B1 105/4885 |
| US-20110086405-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | CYP3A5, CYP1A2, POR | HSD11B1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.